SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-160069
Filing Date
2024-06-12
Accepted
2024-06-12 17:23:01
Documents
14
Period of Report
2024-06-07
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d34301d8k.htm   iXBRL 8-K 40119
2 EX-3.1 d34301dex31.htm EX-3.1 8740
  Complete submission text file 0001193125-24-160069.txt   179100

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akro-20240607.xsd EX-101.SCH 2850
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akro-20240607_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akro-20240607_pre.xml EX-101.PRE 11707
17 EXTRACTED XBRL INSTANCE DOCUMENT d34301d8k_htm.xml XML 3860
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38944 | Film No.: 241039361
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)